Barclays reports 0.00% RVPH stake on amended filing

Barclays PLC filed an amended Schedule 13G reporting its beneficial ownership in Reviva Pharmaceuticals Holdings common stock.

Rhea-AI Filing Summary

Barclays PLC filed an amended Schedule 13G reporting its beneficial ownership in Reviva Pharmaceuticals Holdings common stock. Barclays reports beneficial ownership of 20 shares, representing 0.00% of the class as of June 30, 2026. Barclays has sole voting power and sole dispositive power over all 20 shares, with no shared voting or dispositive power. The filing confirms that Barclays’ holdings are classified as ownership of 5 percent or less of the class.

Key Figures

Shares beneficially owned: 20 shares Percent of class owned: 0.00% Sole voting power: 20 shares +5 more

8 metrics

Shares beneficially owned 20 shares Common stock of Reviva Pharmaceuticals Holdings as of June 30, 2026

Percent of class owned 0.00% Percentage of Reviva Pharmaceuticals Holdings common stock class

Sole voting power 20 shares Shares over which Barclays PLC has sole power to vote

Shared voting power 0 shares Shares over which Barclays PLC has shared power to vote

Sole dispositive power 20 shares Shares over which Barclays PLC has sole power to dispose

Shared dispositive power 0 shares Shares over which Barclays PLC has shared power to dispose

Ownership classification threshold 5 percent or less Barclays PLC states ownership of 5 percent or less of the class

Signature date 08/14/2026 Date the amendment was signed by Director Ramya Rao

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Ownership of 5 percent or less of a class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 20"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 20.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 20.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 percent or less of a class regulatory

"Ownership of 5 percent or less of a class"

parent holding company regulatory

"If a parent holding company has filed this schedule"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in RVPH does Barclays PLC report in this Schedule 13G/A?

Barclays PLC reports beneficial ownership of 20 shares of Reviva Pharmaceuticals Holdings common stock, representing 0.00% of the class, with sole voting and dispositive power over all reported shares.

Does Barclays PLC still hold more than 5% of RVPH according to this filing?

No. Barclays PLC states it has ownership of 5 percent or less of the class, with its reported position of 20 shares representing 0.00% of Reviva Pharmaceuticals Holdings’ common stock.

What voting power over RVPH shares does Barclays PLC report?

Barclays PLC reports sole voting power over 20 shares of Reviva Pharmaceuticals Holdings and no shared voting power, indicating exclusive authority to vote or direct the vote for the reported shares.

What dispositive power over RVPH stock does Barclays PLC disclose?

Barclays PLC discloses sole dispositive power over 20 shares and no shared dispositive power, meaning it alone may determine how these Reviva Pharmaceuticals Holdings shares are disposed of.

When was the RVPH ownership position of Barclays PLC measured and signed?

The reported Reviva Pharmaceuticals Holdings position is as of June 30, 2026, and the amendment was signed by Director Ramya Rao on August 14, 2026 on behalf of Barclays PLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 07:38 PM Accepted by SEC EDGAR 08/13/2026 - 07:38 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

REVIVA PHARMACEUTICALS HOLDI

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

76152G209

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76152G209

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 20.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 20.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

20.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REVIVA PHARMACEUTICALS HOLDI
(b)	Address of issuer's principal executive offices: 10080 N Wolfe Road
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP No.: 76152G209
Item 4.	Ownership
(a)	Amount beneficially owned: 20
(b)	Percent of class: 0.00 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 20
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 20
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	08/14/2026